2024
Transcatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials
Reddy R, Howard J, Reardon M, Thyregod H, Jorgensen T, Toff W, Forrest J, Leon M, Ahmad Y. Transcatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials. European Heart Journal 2024, 45: ehae666.2456. DOI: 10.1093/eurheartj/ehae666.2456.Peer-Reviewed Original ResearchLower-risk patientsIndividual patient dataFollow-upNo significant differenceClinical outcomesPairwise random-effects meta-analysesNew-onset atrial fibrillationLong-term clinical outcomesSurgical aortic valve replacementKaplan-Meier survival curvesMeta-analysis of randomised controlled trialsLow-surgical riskMeta-analysesAortic valve reinterventionReconstructed individual patient dataLow surgical riskAortic valve replacementFollow-up durationSevere aortic stenosisMeta-analysisSignificant differenceCox proportional hazards regressionComposite of deathKaplan-Meier plotsLonger-term follow-up
2016
Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue
Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood 2016, 128: 1188. DOI: 10.1182/blood.v128.22.1188.1188.Peer-Reviewed Original ResearchAutologous stem cell transplantationReconstructed individual patient dataIncremental cost-effectiveness ratioR Hodgkin lymphomaIndividual patient dataHodgkin's lymphomaActive surveillanceOverall survivalHealth care costsHL progressionHL recurrenceHealthcare costsCare costsHigh-risk Hodgkin lymphomaSignificant health care costsDouble-blind trialPatient dataUse of BVFirst-line therapyHigh-dose chemotherapyPrimary refractory diseaseProgression-free survivalStem cell rescueLong-term followStem cell transplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply